Viking Therapeutics Faces License Termination for Key Drug Candidate VK2809; Reports Wider Q1 Loss

summarizeSummary

Viking Therapeutics reported a substantially wider net loss in Q1 2026 and disclosed a dispute with Ligand Pharmaceuticals over the license for its key NASH drug candidate, VK2809, which Ligand is attempting to terminate.

check_boxKey Events

• VK2809 License Termination Dispute

  Ligand Pharmaceuticals notified Viking Therapeutics on April 24, 2026, of its intent to terminate the license for the TR-Beta Program, which includes the VK2809 product candidate. Viking believes Ligand has no right to terminate and plans to vigorously defend its rights.

• Significantly Wider Net Loss

  The company reported a net loss of $158.3 million for Q1 2026, a substantial increase from $45.6 million in Q1 2025, primarily due to a significant rise in research and development expenses.

• Increased R&D Expenses and Cash Burn

  Research and development expenses surged to $150.2 million in Q1 2026 from $41.4 million in Q1 2025, mainly driven by VK2735 Phase 3 clinical trials. Cash used in operating activities increased to $114.0 million from $52.3 million year-over-year.

• CEO Adopts 10b5-1 Trading Plan

  CEO Brian Lian adopted a Rule 10b5-1 trading arrangement on January 15, 2026, to sell 365,000 shares of common stock by December 31, 2026.

auto_awesomeAnalysis

Viking Therapeutics disclosed a significant legal challenge as Ligand Pharmaceuticals is purporting to terminate the license for VK2809, a key product candidate for NASH/MASH. While Viking intends to vigorously defend its rights, the dispute introduces substantial uncertainty and risk to a core asset. This comes alongside a significantly wider net loss and increased cash burn in Q1 2026, primarily driven by higher R&D expenses for its VK2735 Phase 3 trials. The company's liquidity position is noted as sufficient for operations through June 2027, supported by recent ATM offering proceeds. Investors should closely monitor the outcome of the Ligand dispute, as it could materially impact the company's pipeline and future prospects.